Wednesday, January 26, 2022 12:08:33 PM
Yes it does.
The final public offering price per unit will be determined through negotiation between us and the underwriters in this offering and will take into account the recent market price of our common stock, the general condition of the securities market at the time of this offering, the history of, and the prospects for, the industry in which we compete, and our past and present operations and our prospects for future revenues. The recent market price used throughout this prospectus may not be indicative of the public offering price per share.
"Harsh reality is always better than false hope"
Recent SBFM News
- Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R) • ACCESS Newswire • 06/01/2026 12:00:00 PM
- Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology • ACCESS Newswire • 05/29/2026 12:00:00 PM
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing • ACCESS Newswire • 05/28/2026 01:00:00 PM
- Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin • ACCESS Newswire • 05/21/2026 11:00:00 AM
- Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering • ACCESS Newswire • 05/19/2026 04:05:00 PM
- Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering • ACCESS Newswire • 05/18/2026 04:15:00 PM
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
